USRE39892E1 - Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method - Google Patents

Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method Download PDF

Info

Publication number
USRE39892E1
USRE39892E1 US11/484,028 US48402806A USRE39892E US RE39892 E1 USRE39892 E1 US RE39892E1 US 48402806 A US48402806 A US 48402806A US RE39892 E USRE39892 E US RE39892E
Authority
US
United States
Prior art keywords
lactobacillus
lactobacilli
bacteria
species
salivarius
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/484,028
Inventor
Claudio De Simone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8236635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39892(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/484,028 priority Critical patent/USRE39892E1/en
Application granted granted Critical
Publication of USRE39892E1 publication Critical patent/USRE39892E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Definitions

  • the present invention relates to the use of particular species of lactobacilli for preparing pharmaceutical compositions for treatment of vaginal infections, as well as to the pharmaceutical compositions thus prepared, and to methods of treating vaginal infections by administration of said compositions.
  • non-gonococcus infections of the feminine genital system such as, for example: vulvovaginal abscesses and abscesses of Bartholin's (or greater vestibular) gland, endometritis, salpingitis, ovary abscesses and pelvic peritonitis).
  • Bacterial vaginosis is the consequence of a bacterial interaction responsible of substitution at the vagina region of a great number of anaerobic bacteria including Bacteroides, Peptostreptococcus, Peptococcus, Mobiluncus G. vaginalis, for lactobacilli. This syndrome is characterized by a smelly although not particularly irritant secretion. There is only a slight itching and dyspareunia is exceptionally uncommon. Bacterial vaginosis is commonly diagnosed among women that have vaginal trouble, although 50% of women responding to diagnosis criteria for bacterial vaginosis are asymptomatic. Bacterial vaginosis is associated with sexual activity and increases as the number of sexual partners increases; however this affection is not considered as an exclusively sexual-transmission disease.
  • a diagnosis of bacterial vaginosis is given when three of the following four symptoms are encountered:
  • Vaginitis is characterized by an abnormal vaginal secretion, local irritation and vulvar itch.
  • the above are the symptoms of a local infection due to T. vaginalis, or Candida (above all Candida albicans).
  • Vaginosis and symptomatic vaginitis are associated with diabetes, parathyroid insufficiency, altered defenses of the host organism, corti-costeroid treatment, broad-spectrum antibiotic treatment, oral contraceptive drugs and pregnancy. Itch and secretion are the main symptoms of vaginitis due to Candida. Occasionally dyspareunia occurs. Vulva erythema and vulvovaginal thrush can be noticed.
  • For a diagnosis of vaginitis due to Candida the presence of local symptoms is required because usually women can have Candida in the vagina without showing any trouble.
  • This document refers to the following bacteria: Lactobacillus casei, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus casei subs. pseudoplantarum and Lactobacillus crispatus, and suggests bacteria concentrations of 10 3 to 10 10 CFU/g, preferably of about 10 6 CFU/g.
  • compositions exemplified in this document contain Lactobacillus casei and/or Lactobacillus fermentum as the essential components, at concentrations of 1 ⁇ 10 6 CFU/g. Therefore, practically this document teaches that Lactobacillus casei and/or Lactobacillus fermentum are essential components for preparing pharmaceutical compositions for treatment of vaginal infections and that these compositions are efficient at bacteria concentrations of 1 ⁇ 10 6 CFU/g (abbreviation “CFU” means “colony-forming unit”).
  • CFU means “colony-forming unit”.
  • compositions of the known art made in the form of pessaries or tablets for vaginal use, containing lactobacilli, are not sufficiently efficient in re-establishing the vagina colonization. It is further to note that an important proportion of the bacterial cells dies as a result of the physical impact given at the moment of preparation of pessaries and their number is further reduced when they diffuse in the vagina lumen and their propagation should begin.
  • compositions for vaginal use having such good qualities that administration of same to a patient is really beneficial.
  • composition embodiments should be capable of maintaining the number of lactobacilli being propagated constant and ensuring a continuous and constant action in time of said lactobacilli during diffusion of same in the vaginal lumen.
  • lactobacilli-based pharmaceutical compositions greatly efficient for treatment of vaginal infections can be obtained, provided the following features can be met to the highest possible degree:
  • lactobacilli-based pharmaceutical compositions meeting the above features to the highest possible degree, and therefore adapted to be efficiently employed for treatment of vaginal infections, such as vaginitis and vaginosis, for example.
  • vaginal infections such as vaginitis and vaginosis
  • the Applicants have found the lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species meet the whole of the above three features to a greatly higher degree than other lactobacillus species.
  • Another object of the present invention is to provide pharmaceutical compositions adapted to vaginal administration comprising lactobacilli made in the form of: liquid compositions, compositions in the form of a cream or ointment and solid compositions in particular in the form of pessaries and tablets.
  • the object of which in a first aspect thereof, is to provide use of an association of lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species for preparation of a pharmaceutical composition to be employed through vaginal administration for treatment of vaginal infections such as vaginitis and vaginosis, for example.
  • bacteria of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species can be used in combination with one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri.
  • association of bacteria used in the pharmaceutical composition in accordance with the present invention comprises or consists of Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri.
  • lactobacilli Particular examples are:
  • ATCC American Type Culture Collection, 12301 Parklawn Drive, Rockville, Ma. 20852, USA.
  • the bacteria concentration is 10 7 to 10 13 CFU/g, more preferably 10 8 to 10 12 CFU/g, most preferably more than 10 9 to 10 12 CFU/g.
  • each species is present at a concentration of 10 8 to 10 12 CFU/g.
  • the bacterial cultures preferably are in a lyophilized form.
  • compositions of the invention are prepared in a liquid form (solutions for lavages), in the form of creams or ointments, or in a solid form, i.e. as pessaries or vaginal tablets, packets and the like.
  • the pharmaceutical compositions made in the form of tablets can be of a single layer or two or more layers having differentiated release times.
  • compositions of the present invention can be prepared in the form of tablets comprising at least two layers, both containing said species of lactobacilli, bound with usual excipients and additives, so that the release velocity of bacteria the outermost layer is greater than the release velocity of bacteria of the innermost layer.
  • the pharmaceutical compositions of the present invention can be prepared in the form of tablets made up of two layers.
  • Such two layers can be made in such a manner that bacteria in the outer layer are released in a lapse of time of 10-25 minutes, about 15-20 minutes for example, whereas bacteria of the inner layer are released subsequently in a lapse of time of 25-50 minutes, about 30-40 minutes for example.
  • the pharmaceutical compositions also contain a buffer agent capable of maintaining an intervaginal pH stabilized in a gap included between 3 and 5.5 for some hours after administration.
  • the buffer agent is a buffer system consisting of a weak acid selected from any pharmaceutically-acceptable inorganic or organic weak acid, such as boric acid, lactic acid, ascorbic acid, citric acid or acetic acid for example, in combination with the respective sodium salt or another pharmaceutically acceptable salt of the conjugated base of the weak acid used.
  • the pH is buffered in a gap of 4.2 to 4.5 and preferably as the buffer agent it is used a buffer system made up of: lactic acid and sodium lactate or ascorbic acid and sodium ascorbate.
  • compositions of the present invention are flavors, menthol, essence of eucalyptus, methyl salicylate or salicylates as topic refreshing agents, hydrocortisone or other antiinflammatory steroids (0.01 to 500 mg/g), antiphlogistic drugs, antimicrobic and moistening agents (EDTA, dodecaethylene glycol monolaurate, etc.), estriol (0.001 to 1 mg/g) and/or other hormonal substances or substances performing a hormonal activity, maize starch or potato starch, vitamins, anti-oxidants, enzymes (hyaluronidase), heparinoids, lycodaine and other topic anesthetics, plant extracts (Belladonna), zinc, calcium and bismuth.
  • compositions of the invention are practically free of any toxic character and do not give rise to any systemic absorption, so that administration to pregnant patients is also allowed, as well as in case of an allergy to antimycotic and antibacterial drugs.
  • a treatment schedule comprising administration of the composition of the invention in the form of tablets, creams and pessaries to be administered before sleeping, followed by a lavage the next morning is considered as particularly appropriate and efficient.
  • HeLa cells a cell line originating from a human carcinoma of the uterine neck.
  • HeLa cells were maintained as monolayer in tissue-culture bottles in MEM (Minimal Essential Medium) with addition of 10% (v/v) fetal bovine serum (FBS).
  • FBS fetal bovine serum
  • the adhesion reaction was carried out in a multiple-well culture plate for tissues containing a sterile covering slide (24 ⁇ 24 mm) in each well. In each well 1 ml of HeLa cell suspension at a concentration of 1.2 ⁇ 10 5 cells/ml was sown and the plates were incubated for 24 hours at 37° C. in a 5% CO 2 atmosphere.
  • the cells were set with 0.4 ml of May Grumwald per well for 4 minutes, washed with water-diluted Giemsa for 15 minutes before examination with an optical microscope.
  • the processing concentrations were selected based on the percentage of cells having adhering bacteria and the number of bacteria/cell. The maximum adhesion was obtained at concentrations of 5 ⁇ 10 9 bacteria/ml.
  • the quantitative bacterial adhesion is expressed as a percentage of 300 randomly selected cells with adhering bacteria and as average number of adhering bacteria per cell.
  • lactobacilli and Mycetes were used at a final concentration of 5 ⁇ 10 9 /well and 5 ⁇ 10 9 /well, respectively.
  • compositions are intended for preparing tablets, pessaries, creams and liquid solutions for vaginal administration of a microbiotic-culture lyophilized product consisting of an association of several microbic species.
  • Unitary composition for preparing quick-release slightly effervescent tablets comprising carriers and a microbic-culture lyophilized product (1 ⁇ 10 10 CFU/g) consisting of an association of L. brevis ATCC 4006 and L. salivarius subs. salicinius ATCC 11742 (in a 1:1 ratio):
  • Microbic-culture lyophilized product 500 mg Lactose 350 mg Maize starch 200 mg Adipic acid 67 mg Sodium bicarbonate 67 mg Magnesium stearate 11 mg Stearic accid 3 mg Colloidal silica 2 mg
  • the lubricated pallets are then added with 500.0 g of said microbic-culture lyophilized product previously sieved on a 300 ⁇ m mesh, and mixed again for 15 minutes.
  • Pellets thus obtained are submitted to the subsequent compression operation using a rotary compressing machine provided with shaped punches of oval form, so that vaginal-use tablets are obtained of an average weight of 1200 mg.
  • the obtained tablets have a disgregating time of about 15 minutes, by use of the apparatus described in the Farmacopea Ufficiale Italiana.
  • Microbic-culture lyophilized product 500 mg Mannitol 560 mg Hydroxipropyl methylcellulose 80 mg Talc 18 mg Magnesium stearate 19 mg Colloidal silica 3 mg
  • the microbic-culture lyophilized product is calibrated by forcing the spongy mass onto a 270 ⁇ m mesh; the sieved product is added with mannitol, previously sieved on a 279 ⁇ m mesh, hydroxipropyl methylcellulose, talc, magnesium stearate and colloidal silica.
  • the whole mass is mixed for 30 minutes in a Turbula T2A type mixer for powders.
  • the thus obtained mixture is submitted to the subsequent compression operation, using a rotary compressing machine provided with shaped punches of oval form thus obtaining vaginal-use tablets of an average weight of 1200 mg.
  • the obtained tablets have a disgregating time of about 30 minutes, by use of the apparatus described in the Farmacopea Ufficiale Italiana.
  • Unitary composition for preparation of the quick-release layer (it is a slightly effervescent layer):
  • Microbic-culture lyophilized product 250 mg Lactose 240 mg Maize starch 41 mg Adipic acid 30 mg Sodium bicarbonate 30 mg Magnesium stearate 6 mg Stearic accid 2 mg Colloidal silica 1 mg
  • Microbic-culture lyophilized product 250 mg Mannitol 280 mg Hydroxipropyl methylcellulose 50 mg Talc 9 mg Magnesium stearate 10 mg Colloidal silica 1 mg
  • Pellets to be used for the quick-release layer are prepared following the process described in Example 4; mixture to be used for the low-release layer is prepared following the process described in Example 5.
  • the described pellets for the quick-release layer and the described mixture for preparation of the slow-release layer are loaded in two distinct loading hoppers of an appropriate compressing machine, adapted to produce two-layer tablets (Manesty Layer Press type) provided with punches of curved oval form.
  • the machine is such adjusted that two-layer tablets are obtained of an overall average weight of 1200 mg consisting of 2 layers of 600 mg each and each containing 250 mg of the microbic-culture lyophilized product.
  • the obtained two-layer tablets submitted to the disgregaing test using the apparatus described in the Farmacopea Ufficiale Italiana, have a disgregating time of about 15 minutes for the quick-release layer and 30-40 minutes for the slow-release layer.
  • Active ingredient 1 g of the same microbic-culture lyophilized product as in Example 4.
  • VAGINAL CREAM (tube of 10 g)
  • Active ingredient 1 g of the same microbic-culture lyophilized product as in Example 4.
  • Each small bottle contains:
  • Examples 4 to 9 were repeated following the same modalities as specified in said Examples respectively, with the only difference that a microbic-culture lyophilized product was used (concentration 1 ⁇ 10 10 CFU/g) which consisted of L. brevis ATCC 14869, L. salivarius subs. salicinius ATCC 11742 and L. gasseri ATCC 9857 species in a 1:1:1 ratio.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Use of an association of lactobacilli for preparation of a pharmaceutical composition for treatment of vaginosis and vaginitis. Said bacteria association comprises the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, possibly in combination with one or more species selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri.
A pharmaceutical composition comprising said association of lactobacilli adapted for treatment of vaginosis and vaginitis.
A method of treating vaginosis and vaginitis based on administration of said pharmaceutical composition.

Description

FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to the use of particular species of lactobacilli for preparing pharmaceutical compositions for treatment of vaginal infections, as well as to the pharmaceutical compositions thus prepared, and to methods of treating vaginal infections by administration of said compositions.
Normal vagina and normal uterine neck lodge a variety of bacteria assimilable to those of the gastrointestinal system. These bacteria are frequently involved in non-gonococcus infections of the feminine genital system (such as, for example: vulvovaginal abscesses and abscesses of Bartholin's (or greater vestibular) gland, endometritis, salpingitis, ovary abscesses and pelvic peritonitis).
In the progress of inflammatory pelvic diseases of non-venereal nature, often a mixture of anaerobic and aerobic bacteria is found; such a bacteria range may be responsible of infections after gynecological operations, childbirth, abortion, and has been correlated with use of intrauterine devices for preventing impregnation (IUD).
Bacterial vaginosis is the consequence of a bacterial interaction responsible of substitution at the vagina region of a great number of anaerobic bacteria including Bacteroides, Peptostreptococcus, Peptococcus, Mobiluncus G. vaginalis, for lactobacilli. This syndrome is characterized by a smelly although not particularly irritant secretion. There is only a slight itching and dyspareunia is exceptionally uncommon. Bacterial vaginosis is commonly diagnosed among women that have vaginal trouble, although 50% of women responding to diagnosis criteria for bacterial vaginosis are asymptomatic. Bacterial vaginosis is associated with sexual activity and increases as the number of sexual partners increases; however this affection is not considered as an exclusively sexual-transmission disease.
Although bacterial vaginosis is slightly troublesome, it may predispose to development of more serious infections of the genital system, in particular during pregnancy.
A diagnosis of bacterial vaginosis is given when three of the following four symptoms are encountered:
(1) a homogeneous non-inflammatory vaginal secretion, adhering to vagina walls;
(2) a vaginal fluid having pH greater than 4.5;
(3) indicator cells; and
(4) a nauseating smell of the vaginal secretion before or after addition of 10% potassium hydroxide (Whiff's test).
Vaginitis, on the contrary, is characterized by an abnormal vaginal secretion, local irritation and vulvar itch. The above are the symptoms of a local infection due to T. vaginalis, or Candida (above all Candida albicans). Vaginosis and symptomatic vaginitis are associated with diabetes, parathyroid insufficiency, altered defenses of the host organism, corti-costeroid treatment, broad-spectrum antibiotic treatment, oral contraceptive drugs and pregnancy. Itch and secretion are the main symptoms of vaginitis due to Candida. Occasionally dyspareunia occurs. Vulva erythema and vulvovaginal thrush can be noticed. For a diagnosis of vaginitis due to Candida the presence of local symptoms is required because usually women can have Candida in the vagina without showing any trouble.
The results of recent studies have encouraged acknowledgment of the important role accomplished by lactobacilli in keeping a normal bacterial equilibrium within the dynamic ecosystems, such as vagina, and for prevention of genital infections caused by pathogenic organisms.
It is well known that many lactobacilli colonize the vagina of wealthy adult women. They propagate using as an energy source the glycogen secreted from the vaginal mucous membrane and compete with the pathogenic agents from the latter, so as to keep the vaginal lumen defended from the attack of other bacteria. Sulfonamides, antibiotics and disinfectant drugs have been mainly used for treatment of the above mentioned diseases (non-specific vaginitis, vaginosis and vulvar itch, for example). In particular, in the most recent years, with the development of many antibiotics, often antibiotic preparations have been administered to patients. Lactobacilli present in the vagina can succumb to administration of these antibiotics. Unfortunately, pathogenic bacteria (Staphylococcus, for example) can acquire a resistance to antibiotics and thus make it difficult to treat these diseases by administering antibiotics.
In U.S. Pat. No. 5,176,911 use of lactobacilli has been proposed in gynecology for treatment of vaginal infections.
This document refers to the following bacteria: Lactobacillus casei, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus casei subs. pseudoplantarum and Lactobacillus crispatus, and suggests bacteria concentrations of 103 to 1010 CFU/g, preferably of about 106 CFU/g.
However, all compositions exemplified in this document contain Lactobacillus casei and/or Lactobacillus fermentum as the essential components, at concentrations of 1×106 CFU/g. Therefore, practically this document teaches that Lactobacillus casei and/or Lactobacillus fermentum are essential components for preparing pharmaceutical compositions for treatment of vaginal infections and that these compositions are efficient at bacteria concentrations of 1×106 CFU/g (abbreviation “CFU” means “colony-forming unit”).
Pharmaceutical compositions of the known art, made in the form of pessaries or tablets for vaginal use, containing lactobacilli, are not sufficiently efficient in re-establishing the vagina colonization. It is further to note that an important proportion of the bacterial cells dies as a result of the physical impact given at the moment of preparation of pessaries and their number is further reduced when they diffuse in the vagina lumen and their propagation should begin.
Therefore, there is a need to dispose of appropriate species of lactobacilli, or mixtures thereof, and of pharmaceutical compositions containing them, which are free of the drawbacks of the known art compositions.
In particular there is need for pharmaceutical compositions for vaginal use having such good qualities that administration of same to a patient is really beneficial.
In addition, the pharmaceutical composition embodiments should be capable of maintaining the number of lactobacilli being propagated constant and ensuring a continuous and constant action in time of said lactobacilli during diffusion of same in the vaginal lumen.
The Applicants have found that lactobacilli-based pharmaceutical compositions greatly efficient for treatment of vaginal infections can be obtained, provided the following features can be met to the highest possible degree:
    • (a) the selected lactobacillus strain must have a high affinity towards the vaginal epithelium, i.e. a high capability of adhering to the epithelial cells of the vagina, in that this property enables bacteria interaction with the vagina mucosa under both physiological and pathological conditions (thus performing a competitive action with the pathogenic microorganisms in the epithelial receptor sites) and re-establishment of microflora and optimal pH conditions;
    • (b) at least one selected lactobacillus strain must have a high capability of producing hydrogen peroxide performing an inhibiting action addressed to the pathogenic microorganisms; and
    • (c) at least one selected lactobacillus strain must be characterized by a high capability of interfering in a competitive manner with adhesion of the Candida albicans to HeLa cells.
SUMMARY OF THE INVENTION
Therefore, it is an object of the present invention to provide lactobacilli-based pharmaceutical compositions meeting the above features to the highest possible degree, and therefore adapted to be efficiently employed for treatment of vaginal infections, such as vaginitis and vaginosis, for example. In this connection the Applicants have found the lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species meet the whole of the above three features to a greatly higher degree than other lactobacillus species.
Another object of the present invention is to provide pharmaceutical compositions adapted to vaginal administration comprising lactobacilli made in the form of: liquid compositions, compositions in the form of a cream or ointment and solid compositions in particular in the form of pessaries and tablets.
It is a further object of the invention to provide solid pharmaceutical compositions capable fo releasing lactobacilli carried therein in a differentiated manner in time.
The foregoing and further objects that will become apparent in the progress of the following detailed description are achieved by the present invention the object of which, in a first aspect thereof, is to provide use of an association of lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species for preparation of a pharmaceutical composition to be employed through vaginal administration for treatment of vaginal infections such as vaginitis and vaginosis, for example.
In another aspect, it is an object of the present invention to provide said pharmaceutical composition.
In a still further aspect, it is an object of the present invention to provide a method of treating vaginal infections in which said pharmaceutical composition is administered.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In particular embodiments of the present invention bacteria of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species can be used in combination with one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri.
Preferably, association of bacteria used in the pharmaceutical composition in accordance with the present invention comprises or consists of Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri.
Particular examples of lactobacilli to be used are:
Lactobacillus brevis ATCC 4006 and ATCC 14869
Lactobacillus salivarius subs. salicinius ATCC 11742
Lactobacillus gasseri ATCC 9857
By ATCC it is intended American Type Culture Collection, 12301 Parklawn Drive, Rockville, Ma. 20852, USA.
Preferably, in the association of bacteria employed in accordance with the present invention the bacteria concentration is 107 to 1013 CFU/g, more preferably 108 to 1012 CFU/g, most preferably more than 109 to 1012 CFU/g. Preferably, in said association of bacteria each species is present at a concentration of 108 to 1012 CFU/g.
The bacterial cultures preferably are in a lyophilized form.
For practical use the pharmaceutical compositions of the invention are prepared in a liquid form (solutions for lavages), in the form of creams or ointments, or in a solid form, i.e. as pessaries or vaginal tablets, packets and the like. The pharmaceutical compositions made in the form of tablets can be of a single layer or two or more layers having differentiated release times.
In particular, the pharmaceutical compositions of the present invention can be prepared in the form of tablets comprising at least two layers, both containing said species of lactobacilli, bound with usual excipients and additives, so that the release velocity of bacteria the outermost layer is greater than the release velocity of bacteria of the innermost layer.
By way of example, the pharmaceutical compositions of the present invention can be prepared in the form of tablets made up of two layers. Such two layers can be made in such a manner that bacteria in the outer layer are released in a lapse of time of 10-25 minutes, about 15-20 minutes for example, whereas bacteria of the inner layer are released subsequently in a lapse of time of 25-50 minutes, about 30-40 minutes for example.
In a preferred embodiment of the present invention, the pharmaceutical compositions also contain a buffer agent capable of maintaining an intervaginal pH stabilized in a gap included between 3 and 5.5 for some hours after administration. The buffer agent is a buffer system consisting of a weak acid selected from any pharmaceutically-acceptable inorganic or organic weak acid, such as boric acid, lactic acid, ascorbic acid, citric acid or acetic acid for example, in combination with the respective sodium salt or another pharmaceutically acceptable salt of the conjugated base of the weak acid used. Preferably, the pH is buffered in a gap of 4.2 to 4.5 and preferably as the buffer agent it is used a buffer system made up of: lactic acid and sodium lactate or ascorbic acid and sodium ascorbate.
Further components or ingredients that can be possibly included in the preparations of the present invention are flavors, menthol, essence of eucalyptus, methyl salicylate or salicylates as topic refreshing agents, hydrocortisone or other antiinflammatory steroids (0.01 to 500 mg/g), antiphlogistic drugs, antimicrobic and moistening agents (EDTA, dodecaethylene glycol monolaurate, etc.), estriol (0.001 to 1 mg/g) and/or other hormonal substances or substances performing a hormonal activity, maize starch or potato starch, vitamins, anti-oxidants, enzymes (hyaluronidase), heparinoids, lycodaine and other topic anesthetics, plant extracts (Belladonna), zinc, calcium and bismuth.
For preparation of water formulations for lavages and irrigations, small bottles are used that are provided with reservoirs containing the lyophilized microorganisms to be dissolved before use in an appropriate liquid medium separately contained in the small bottles. The compositions of the invention are practically free of any toxic character and do not give rise to any systemic absorption, so that administration to pregnant patients is also allowed, as well as in case of an allergy to antimycotic and antibacterial drugs.
According to the hitherto acquired clinical experience, a treatment schedule comprising administration of the composition of the invention in the form of tablets, creams and pessaries to be administered before sleeping, followed by a lavage the next morning is considered as particularly appropriate and efficient.
After describing the present invention in a general manner, the same will be better understood referring it to some specific examples given hereinafter for illustrative purposes only which are not to be intended in a limiting sense.
EXAMPLES Example 1 Adhesion Lactobacilli to HeLa Cells
By this test there was examined the capability of different strains of Lactobacilli from the American Type Culture Collection (ATCC) to adhere to HeLa cells, a cell line originating from a human carcinoma of the uterine neck. HeLa cells were maintained as monolayer in tissue-culture bottles in MEM (Minimal Essential Medium) with addition of 10% (v/v) fetal bovine serum (FBS). The adhesion reaction was carried out in a multiple-well culture plate for tissues containing a sterile covering slide (24×24 mm) in each well. In each well 1 ml of HeLa cell suspension at a concentration of 1.2×105 cells/ml was sown and the plates were incubated for 24 hours at 37° C. in a 5% CO2 atmosphere. Before the adhesion test, all bacterial strains were placed in a MRS broth sub-culture (Difco). After a 24 hour incubation at 37° C. under anaerobic conditions (15% CO2) the bacteria were “strengthened” in a new broth and then incubated overnight under the same experimental conditions. An anaerobic environment was obtained by incubating the bacteria in a jar containing specific bags of “Anaerogen” (Oxoid). For the adhesion test, different dilutions of bacterial suspension in MEM were incubated on cell monolayers over one hour at 37° C. under microaerophilic conditions. After several washings in PBS to remove the microorganisms that did not adhere, the cells were set with 0.4 ml of May Grumwald per well for 4 minutes, washed with water-diluted Giemsa for 15 minutes before examination with an optical microscope. The processing concentrations were selected based on the percentage of cells having adhering bacteria and the number of bacteria/cell. The maximum adhesion was obtained at concentrations of 5×109 bacteria/ml.
The obtained results set forth in Table 1, show that tested lactobacilli were capable of adhering to HeLa cells, showing different adhesion degrees to the host cells. The highest adhesion degrees were found in Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species. Lactobacillus case, in addition to having a low adhesion degree, is invasive and therefore is not adapted for preparation of the pharmaceutical composition of the present invention.
TABLE 1
Adhesion of different lactobacillus strains to HeLa cells.
Bacterial adhesion
No. of % Cells
adhering with adhering
Lactobacilli bacteria/cell bacteria Invasiveness (a)
A) L. salivarius 15 60 −
subs. salicinius
(ATCC 11742)
B) L. brevis 35 100  −
(ATCC 4006)
C) L. brevis 35 100  −
(ATCC 14869)
D) L. crispatus 10 45 +/−
(ATCC 33197)
E) L. gasseri  5 16 −
(ATCC 9857)
F) L. casei  8 19 +
(ATCC 8530)
(a) + = invasive; +/− = slightly invasive; − = non invasive.
The quantitative bacterial adhesion is expressed as a percentage of 300 randomly selected cells with adhering bacteria and as average number of adhering bacteria per cell.
Example 2 Anti Candida Effect of Lactobacilli
The capability of various lactobacillus species of interfering in a competitive manner with adhesion of the Candida albicans (and therefore on the Candida albicans infectiveness) to HeLa cells was examined.
In order to evaluate the lactobacillus influence on the adhesion level of Mycetes (C. albicans) to host cells, mono-layer HeLa cells, grown up in 24-well plates containing sterile covering slides were inoculated with 0.1 ml of a mixture of lactobacilli and C. albicans (two clinical samples isolated from a human vagina referred to in this study as CA2 and CA3, respectively) diluted in PBS at final concentrations of 5×109 bacteria/ml and 5×108 Mycetes/ml, respectively. After one hour of incubation at 37° C. under microaerophilic conditions, cells were washed five times in PBS set with May Grunwald and Giemsa. Then slides were controlled with an optical microscope (1000×magnification) and the level of microorganisms adhering to HeLa cells was evaluated. The obtained results, set forth in Table 2, show that all tested lactobacilli are capable of reducing adhesion of C. albicans to HeLa cells, the highest inhibitory-activity degree being shown by L. brevis ATCC 4006, which produced a reduction of about 50% in the number of cells with adhered Candida and reduced the number of Mycetes/cell to about half the control number.
TABLE 2
Competitive exclusion of C. albicans adhesion to HeLa
cells by lactobacilli
Average No. of
% cells with microorganisms/cell
Microorganism Mycetes bacteria Mycetes bacteria
CA2 68 5
CA3 61 7
A) L. salivarius 54 10
subs. salicinius
ATCC 11742
B) L. bervis 95 20
ATCC 4006
C) L. gasseri 15  6
ATCC 9857
D) L. casei 13  8
ATCC 8530
CA2 + A 52 55 3 10
CA3 + A 43 54 3 11
CA2 + B 44 99 3 20
CA3 + B 34 99 2 20
CA2 + C 48 15 4  6
CA3 + C 57 16 5  5
CA2 + D 61 12 5  7
CA3 + D 58 12 5  7
For the competitive-exclusion test, lactobacilli and Mycetes were used at a final concentration of 5×109/well and 5×109/well, respectively.
Example 3 Production of Hydrogen Peroxide by Lactobacilli
The capability of five lactobacilli species of producing H2O2 was examined. Bacteria were placed for culture on an agar-agar plate with tetramethylbenzidine. After three days of incubation at 37° C. in a jar under anaerobic conditions, the agar-agar plates were exposed to the air. In this way, the peroxidase present in the culture medium reacts with the H2O2 produced by lactobacilli. The subsequent oxidation of tetramethylbenzidine is revealed by a blue pigmentation of the H2O2-producing colonies. The obtained results, set forth in Table 3, show that L. salivarius subs. salicinius ATCC 11742 and L. gasseri ATCC 3857 were positive to H2O2.
L. casei ATCC 8530 did not show any positivity. The other tested strains were devoid of any reaction. These results show that no correlation exists between the H2O2 production by lactobacilli and the competitive exclusion of the C. albicans adhesion to HeLa cells by bacteria.
TABLE 3
Production of hydrogen peroxide by lactobacilli
Lactobacilli Production of H2O2
A) Lactobacillus salivarius +
subs. salicinius (ATCC 11742)
B) Lactobacillus brevis −
(ATCC 4006)
C) Lactobacillus brevis −
(ATCC 14869)
D) Lactobacillus gasseri +
(ATCC 3857)
E) L. casei −
(ATCC 8530)
+ = blue pigmentation of all bacteria colonies.
+/− = light blue pigmentation.
− = no pigmented colony.
For illustrative purposes, but not in a limiting sense, some examples of preferred pharmaceutical compositions are reproduced hereinafter, which compositions are intended for preparing tablets, pessaries, creams and liquid solutions for vaginal administration of a microbiotic-culture lyophilized product consisting of an association of several microbic species.
Examples of Vaginal Reparations Example 4
Unitary composition for preparing quick-release slightly effervescent tablets comprising carriers and a microbic-culture lyophilized product (1×1010 CFU/g) consisting of an association of L. brevis ATCC 4006 and L. salivarius subs. salicinius ATCC 11742 (in a 1:1 ratio):
Microbic-culture lyophilized product 500 mg
Lactose 350 mg
Maize starch 200 mg
Adipic acid  67 mg
Sodium bicarbonate  67 mg
Magnesium stearate  11 mg
Stearic accid  3 mg
Colloidal silica  2 mg
For preparation of tablets having the above composition, previous preparation of a granulate or pellets is required.
The lubricated pallets are then added with 500.0 g of said microbic-culture lyophilized product previously sieved on a 300 μm mesh, and mixed again for 15 minutes. Pellets thus obtained are submitted to the subsequent compression operation using a rotary compressing machine provided with shaped punches of oval form, so that vaginal-use tablets are obtained of an average weight of 1200 mg.
The obtained tablets have a disgregating time of about 15 minutes, by use of the apparatus described in the Farmacopea Ufficiale Italiana.
Example 5
Unitary composition for preparing slow-release tablets comprising carriers and the same microbic-culture lyophilized product as in Example 4:
Microbic-culture lyophilized product 500 mg
Mannitol 560 mg
Hydroxipropyl methylcellulose  80 mg
Talc  18 mg
Magnesium stearate  19 mg
Colloidal silica  3 mg
The microbic-culture lyophilized product is calibrated by forcing the spongy mass onto a 270 μm mesh; the sieved product is added with mannitol, previously sieved on a 279 μm mesh, hydroxipropyl methylcellulose, talc, magnesium stearate and colloidal silica. The whole mass is mixed for 30 minutes in a Turbula T2A type mixer for powders. The thus obtained mixture is submitted to the subsequent compression operation, using a rotary compressing machine provided with shaped punches of oval form thus obtaining vaginal-use tablets of an average weight of 1200 mg.
The obtained tablets have a disgregating time of about 30 minutes, by use of the apparatus described in the Farmacopea Ufficiale Italiana.
Example 6
Preparation of two-layer (one quick-release layer and one slow-release layer) tablets comprising carriers and the same microbic-culture lyophilized product as in Example 4.
Unitary composition for preparation of the quick-release layer (it is a slightly effervescent layer):
Microbic-culture lyophilized product 250 mg
Lactose 240 mg
Maize starch  41 mg
Adipic acid  30 mg
Sodium bicarbonate  30 mg
Magnesium stearate  6 mg
Stearic accid  2 mg
Colloidal silica  1 mg
Unitary composition for preparation of the slow-release layer:
Microbic-culture lyophilized product 250 mg
Mannitol 280 mg
Hydroxipropyl methylcellulose  50 mg
Talc  9 mg
Magnesium stearate  10 mg
Colloidal silica  1 mg
Pellets to be used for the quick-release layer are prepared following the process described in Example 4; mixture to be used for the low-release layer is prepared following the process described in Example 5.
The described pellets for the quick-release layer and the described mixture for preparation of the slow-release layer are loaded in two distinct loading hoppers of an appropriate compressing machine, adapted to produce two-layer tablets (Manesty Layer Press type) provided with punches of curved oval form.
The machine is such adjusted that two-layer tablets are obtained of an overall average weight of 1200 mg consisting of 2 layers of 600 mg each and each containing 250 mg of the microbic-culture lyophilized product.
The obtained two-layer tablets, submitted to the disgregaing test using the apparatus described in the Farmacopea Ufficiale Italiana, have a disgregating time of about 15 minutes for the quick-release layer and 30-40 minutes for the slow-release layer.
Example 7
Active ingredient: 1 g of the same microbic-culture lyophilized product as in Example 4.
Excipients: 2.5 g of semisynthetic glycerides and potato starch.
Example 8
VAGINAL CREAM (tube of 10 g)
Active ingredient: 1 g of the same microbic-culture lyophilized product as in Example 4.
Excipients: hydrogenated lanolin (2 g), Vaseline oil (2 g), dimethyl polysiloxane (3 g), SiO2 (4 g).
Example 9
SMALL BOTTLES WITH RESERVOIR
Each small bottle contains:
    • a) Reservoir: 2 g of the same microbic-culture lyophilized product as in Example 4.
    • b) Small bottle (10 ml): glycerol 3 g and water in a sufficient amount to 10 ml.
Examples 10 to 15
Examples 4 to 9 were repeated following the same modalities as specified in said Examples respectively, with the only difference that a microbic-culture lyophilized product was used (concentration 1×1010 CFU/g) which consisted of L. brevis ATCC 14869, L. salivarius subs. salicinius ATCC 11742 and L. gasseri ATCC 9857 species in a 1:1:1 ratio.
All pharmaceutical preparations obtained in Examples 4 to 15 have proved to be very efficient in treating patients suffering from vaginosis and vaginitis.

Claims (8)

1. A composition comprising lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, in the form of pessaries or vaginal tablets comprising at least two layers, both layers containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer.
2. The composition as claimed in claim 1, wherein said composition further comprises one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri.
3. The composition as claimed in claim 2, wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species.
4. The composition as claimed in claim 1, wherein said lactobacilli are present at a concentration of 107 to 1013 CFU/g.
5. A method of treatment of a vaginal infection, comprising administering through the vagina a composition comprising lactobacilli of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, in the form of pessaries or vaginal tablets comprising at least two layers, both layers containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer.
6. The method of claim 5, said composition further comprises one or more species of lactobacilli selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri.
7. The method of claim 6, wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species.
8. The method of claim 5, wherein said lactobacilli are present at a concentration of 107 to 1013 CFU/g.
US11/484,028 1998-04-30 2006-07-11 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method Expired - Lifetime USRE39892E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/484,028 USRE39892E1 (en) 1998-04-30 2006-07-11 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98830264A EP0956858B1 (en) 1998-04-30 1998-04-30 Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for treatment of vaginal infections
US09/185,572 US6277370B1 (en) 1998-04-30 1998-11-04 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
US11/484,028 USRE39892E1 (en) 1998-04-30 2006-07-11 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/185,572 Reissue US6277370B1 (en) 1998-04-30 1998-11-04 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Publications (1)

Publication Number Publication Date
USRE39892E1 true USRE39892E1 (en) 2007-10-23

Family

ID=8236635

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/185,572 Ceased US6277370B1 (en) 1998-04-30 1998-11-04 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
US11/484,028 Expired - Lifetime USRE39892E1 (en) 1998-04-30 2006-07-11 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/185,572 Ceased US6277370B1 (en) 1998-04-30 1998-11-04 Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method

Country Status (16)

Country Link
US (2) US6277370B1 (en)
EP (1) EP0956858B1 (en)
JP (1) JPH11322621A (en)
KR (1) KR100590839B1 (en)
CN (1) CN1263467C (en)
AR (1) AR017404A1 (en)
AT (1) ATE207755T1 (en)
AU (1) AU745286B2 (en)
BR (1) BR9900972A (en)
CA (1) CA2254548C (en)
DE (1) DE69802260T2 (en)
DK (1) DK0956858T3 (en)
ES (1) ES2165139T3 (en)
HU (1) HU225491B1 (en)
PL (1) PL189577B1 (en)
PT (1) PT956858E (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
FR2778187B1 (en) * 1998-04-30 2001-06-22 Sanofi Elf METHOD FOR SELECTING BACTERIAL STRAINS
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
IT1306716B1 (en) * 1999-06-21 2001-10-02 Mendes S U R L ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES.
CN101862449A (en) * 2000-06-19 2010-10-20 亨特免疫有限公司 Be used for the treatment of oidiomycotic compositions and method
SI1312667T1 (en) 2000-08-25 2009-04-30 Wakamoto Pharma Co Ltd Probiotic products containing L. salivarius strain
SE521022C2 (en) 2001-09-20 2003-09-23 Ellen Ab Lactic acid producing bacteria for use as probiotic organisms in the human vagina
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
WO2004007695A2 (en) * 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
SI1485463T1 (en) 2002-03-21 2009-02-28 Bifodan As Lactobacillus strains
US7829079B2 (en) * 2002-03-28 2010-11-09 Christian Hansen A/S Lactobacillus iners for the enhancement of urogenital health
JP2004067599A (en) * 2002-08-07 2004-03-04 Kunihiko Tominaga In-vagina detergent
US20040071679A1 (en) * 2002-10-15 2004-04-15 Claudio De Simone Identifying and treating vaginal infections
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
ATE289514T1 (en) * 2003-11-03 2005-03-15 Peter-Hansen Volkmann VAGINAL CARE COMPOSITION
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
EP1786445B1 (en) 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Live microbial microbicides
WO2006045474A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same
WO2006045347A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
ES2433926T3 (en) * 2004-12-23 2013-12-13 Actial Farmacêutica, Lda. Device and procedure to identify vaginal conditions
WO2006083516A2 (en) * 2005-01-12 2006-08-10 Osel, Inc. Modified cyanovirin-n polypeptide
JP2008540534A (en) * 2005-05-09 2008-11-20 ドラッグテック コーポレイション Modified release pharmaceutical composition
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US20070082035A1 (en) * 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
KR20080083190A (en) * 2006-01-05 2008-09-16 드러그테크 코포레이션 Drug delivery system for bioadhesion to the vulvar surface
US20070224226A1 (en) * 2006-01-05 2007-09-27 Drugtech Corporation Composition and method of use thereof
ITMI20062286A1 (en) * 2006-11-28 2008-05-29 Anidral Srl A COMPOSITION FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE PRINCIPLES IN GYNECOLOGICAL AND RECTAL AREA AS WELL AS ITS USES
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
PL210465B1 (en) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus
CN102028224B (en) * 2007-06-21 2012-12-26 东宇生物科技股份有限公司 Anti-allergic lactic acid bacteria
EP1930044B1 (en) * 2007-07-26 2017-08-23 Elisabetta Livi Two-phase vaginal lavage
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
TWI542353B (en) * 2010-04-30 2016-07-21 豐華生物科技股份有限公司 Anti-vaginitis food composition and pharmaceutical composition containing lactobacillus
TWI451871B (en) * 2010-04-30 2014-09-11 Glac Biotech Co Ltd Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus
IT1403661B1 (en) * 2011-01-28 2013-10-31 Probiotical Spa EFFERVESCENT COMPOSITION IN THE SOLID FORM FOR USE IN VAGINAL APPLICATIONS FOR THE TREATMENT OF VAGINAL INFECTIONS.
ITMI20110793A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
ITMI20110791A1 (en) 2011-05-09 2012-11-10 Probiotical Spa BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
ITRM20110477A1 (en) 2011-09-09 2013-03-10 Giovanni Mogna COMPOSITION INCLUDING N-ACETYLCISTEIN AND / OR LYSOZYME MICROINCAPSULATE GASTROPROTECT IN ASSOCIATION WITH PROBIOTIC BACTERES ABLE TO RESTORE THE BARRIER EFFECT OF THE STOMACH THAT IS LOST DURING THE PHARMACOLOGICAL TREATMENT OF
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
KR101355441B1 (en) * 2011-11-03 2014-01-27 주식회사한국야쿠르트 Lactobacillus johnsonii HY7042 helpful to maintain healthy vaginal environment and products containing thereof as effective component
FR2992861B1 (en) * 2012-07-09 2014-10-17 Probionov USE OF THIOSULFATE FOR POTENTIATING THE ANTI-PATHOGENIC EFFECT OF LACTOBACILLES
ITMI20130793A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.
MX2016014991A (en) * 2014-05-16 2017-09-11 Pizeta Group Srl Compositions containing boric acid and a mixture of lactobacillus.
KR101860552B1 (en) 2015-04-16 2018-07-02 주식회사 고바이오랩 Lactobacilli having inhibitory effect against pathogenic microorganisms in vagina
CN113564075A (en) * 2015-06-29 2021-10-29 辉凌制药公司 Lactobacillus rhamnosus bacteria for the treatment of e.g. bacterial vaginosis
CN105287644B (en) * 2015-09-14 2018-12-28 吉林农业大学 The probiotic combinations active bacteria formulation for treating milk cow recessive endometritis
EP3167890A1 (en) 2015-11-12 2017-05-17 Glock Health, Science and Research GmbH Treatment of vaginitis
FR3048361B1 (en) * 2016-03-01 2020-12-18 Biose COMPOSITIONS FOR THE TREATMENT OF CANDIDOSES
MA45334A (en) 2016-03-24 2019-01-30 Probiotical Spa BACTERIAL COMPOSITION OF LACTIC ACID FOR THE TREATMENT OF BACTERIAL VAGINAL INFECTIONS WITH GARDNERELLA VAGINALIS AND, POSSIBLE, CONCURRENT FUNGAL INFECTIONS
JP2019529572A (en) * 2016-10-04 2019-10-17 エボフェム・インコーポレイテッド Methods for treating and preventing bacterial vaginosis
CN106692204B (en) * 2017-03-10 2020-05-22 泰安大凡神农生物有限公司 Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof
CN106957811B (en) * 2017-05-22 2019-11-26 山东神农医院管理有限公司 Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation
DE102017113263A1 (en) 2017-06-16 2018-12-20 Lactopia GmbH Pharmaceutical composition containing bacterial strains of the family Lactobacillaceae and whey
CN110540945B (en) * 2018-05-29 2023-04-25 广东强基药业有限公司 Lactobacillus jensenii and application thereof in preparing vaginal antibacterial drugs
IT201800020425A1 (en) 2018-12-20 2020-06-20 Univ Degli Studi Di Modena E Reggio Emilia LATTOBACILLI WITH ANTIMICROBIAL ACTIVITY
PE20220381A1 (en) * 2019-04-05 2022-03-18 Gedea Biotech Ab VAGINAL TABLET FORMULATION
JP2021042172A (en) * 2019-09-12 2021-03-18 株式会社アノワ Composition for application to female dz
WO2024130454A1 (en) * 2022-12-21 2024-06-27 Universidad de Concepción Probiotic formulation with synergistic effect in inhibiting nosocomial bacterial pathogens
CN117180302B (en) * 2023-11-06 2024-01-12 山东中医药大学第二附属医院(山东省中西医结合医院) Application of polysaccharide in repairing oral mucosa and accelerator prepared from polysaccharide

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591499A (en) * 1984-01-20 1986-05-27 J. B. Lima, Inc. Method for treatment and prevention of mastitis
EP0353581A2 (en) * 1988-08-05 1990-02-07 Dr. A. Tosi Farmaceutici S.R.L. Pharmaceutical compositions comprising selected lactobacillus strains
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
WO1994006416A1 (en) * 1992-09-24 1994-03-31 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
WO1995033046A1 (en) * 1994-05-26 1995-12-07 Bracco S.P.A. Lactobacillus strains of human origin, their compositions and uses thereof
WO1996038159A1 (en) * 1995-06-02 1996-12-05 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
US5705160A (en) * 1985-12-31 1998-01-06 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
HU214991B (en) * 1991-01-17 1998-10-28 Ernő Méhész Composition containing complett in vitro lactobacilles media an process for producing thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6018644B2 (en) * 1974-11-07 1985-05-11 財団法人成研会 Method for manufacturing vaginal suppositories
JPS59122425A (en) * 1982-12-27 1984-07-14 Kaken Pharmaceut Co Ltd Sustained release preparation and its preparation
RU2031586C1 (en) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Biologically active product of sour milk and method for its production
ZA942302B (en) * 1993-12-03 1995-09-29 Lafor Lab Ltd Viracidal bactericidal and spermicidal vaginal suppository
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
JPH08298982A (en) * 1995-05-02 1996-11-19 Aasu Giken:Kk Complex microbial pharmaceutical preparation
JPH092959A (en) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd IgE antibody production inhibitor and antiallergic agent
JPH11504048A (en) * 1996-02-14 1999-04-06 ザ、プロクター、エンド、ギャンブル、カンパニー Genitourinary and intestinal compositions
JP4021951B2 (en) * 1996-03-01 2007-12-12 わかもと製薬株式会社 Anti-gastritis, anti-ulcer and fermented food containing lactic acid bacteria as active ingredients

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591499A (en) * 1984-01-20 1986-05-27 J. B. Lima, Inc. Method for treatment and prevention of mastitis
US5705160A (en) * 1985-12-31 1998-01-06 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
EP0353581A2 (en) * 1988-08-05 1990-02-07 Dr. A. Tosi Farmaceutici S.R.L. Pharmaceutical compositions comprising selected lactobacillus strains
HU214991B (en) * 1991-01-17 1998-10-28 Ernő Méhész Composition containing complett in vitro lactobacilles media an process for producing thereof
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
WO1994006416A1 (en) * 1992-09-24 1994-03-31 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
WO1995033046A1 (en) * 1994-05-26 1995-12-07 Bracco S.P.A. Lactobacillus strains of human origin, their compositions and uses thereof
WO1996038159A1 (en) * 1995-06-02 1996-12-05 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATCC Catalog of Bacteria and Bacteriophages, 19<SUP>th </SUP>Ed. p. 198 (1996). *
Dembele et al., "Inhibition of Bacterial Pathogens by Lacotbacilli", Zent.bl. Bakteriol. 288 : 395-401 (1998). *
Giorgi et al., "Identification of vaginal lactobacilli from asymptomatic women", Microbiologica (Bologna) 10 (4) : 377-384 (1987). *

Also Published As

Publication number Publication date
CN1263467C (en) 2006-07-12
US6277370B1 (en) 2001-08-21
HK1022439A1 (en) 2000-08-11
DE69802260D1 (en) 2001-12-06
CA2254548C (en) 2009-07-14
PL329780A1 (en) 1999-11-08
HUP9802525A3 (en) 2000-06-28
BR9900972A (en) 2000-03-28
PT956858E (en) 2002-04-29
EP0956858B1 (en) 2001-10-31
KR19990083612A (en) 1999-11-25
DK0956858T3 (en) 2002-01-28
HU9802525D0 (en) 1999-01-28
HU225491B1 (en) 2006-12-28
JPH11322621A (en) 1999-11-24
ES2165139T3 (en) 2002-03-01
AU9240098A (en) 1999-11-11
PL189577B1 (en) 2005-08-31
CA2254548A1 (en) 1999-10-30
HUP9802525A1 (en) 1999-12-28
AR017404A1 (en) 2001-09-05
AU745286B2 (en) 2002-03-21
ATE207755T1 (en) 2001-11-15
DE69802260T2 (en) 2002-07-04
KR100590839B1 (en) 2006-06-19
CN1233474A (en) 1999-11-03
EP0956858A1 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
USRE39892E1 (en) Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method
Maggi et al. Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration
Sobel Candidal vulvovaginitis
KR100336183B1 (en) Virus killing, bactericidal and spermicide suppositories
Melekos et al. Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women
SCHMITT et al. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole
US20060062774A1 (en) Compositions for maintaining and restoring normal urogenital flora
US6537538B2 (en) Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
US10016358B2 (en) Vaginal suppository comprising lactic acid
Richardson et al. Use of nonoxynol-9 and changes in vaginal lactobacilli
EP3941499B1 (en) A composition for competitive inhibition of pathogens and restoration of microbial ecological balance
HU219814B (en) Viracidal, bactericidal and spermicidal vaginal suppository and other vaginal pessary
EP4247334B1 (en) Pharmaceutical composition for use in the prevention or treatment of a condition associated with a reduction in the number of lactobacilli in the vagina
Mokwele et al. Bacterial vaginosis: An overview
CN110693811A (en) Vaginal expansion suppository containing lactobacillus and lactose and preparation method thereof
EP2886117B1 (en) Topical compositions for the treatment of Gardnerella vaginalis infections
US20250009815A1 (en) Composition for competitive inhibition of pathogens and restoration of microbial ecological balance
HK1022439B (en) Pharmaceutical compositions containing lactobacilli for treatment fo vaginal infections
POLOVA et al. DEVELOPMENT ACTUALITY OF VAGINAL SUPPOSITORIES WITH LACTOBACILLUS CASEI
Ndzamba et al. Bacterial vaginosis: an overview
Mikamo et al. Study on treatment of bacterial vaginosis with oral administration of metronidazole or cefdinir
Ogunshe et al. Soaps and Disinfectants/Germicides as Adjunct Antimycotic Cleansing-Agents in Cases of Vulvovaginal Candidasis
Benrubi Vulvar and Vaginal Diseases

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
REIN Reinstatement after maintenance fee payment confirmed
FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment
PRDP Patent reinstated due to the acceptance of a late maintenance fee

Effective date: 20071023

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11